The IL-1β signaling axis as a prognostic determinant in early-stage breast cancer: integrated analysis of tumor and circulating biomarkers.
- 1Department of Dentistry, College of Medicine, Komar University of Science and Technology, Chaq-Chaq-Qualaraisi, Sulaimani City, Iraq.
Abstract
Background
Chronic inflammation contributes to breast cancer progression, yet the prognostic relevance of inflammatory signaling pathways in early-stage disease remains incompletely defined. Interleukin-1β (IL-1β) is a key pro-inflammatory cytokine regulated by inflammasome activation and receptor-mediated signaling. This study evaluated the clinical and prognostic significance of major IL-1β pathway components in early-stage invasive breast cancer.Methods
A retrospective cohort of 562 patients with early-stage invasive breast cancer treated between 2018 and 2025 was analyzed. Tissue microarrays were constructed, and immunohistochemistry was used to assess intratumoral expression of caspase-1, IL-1 receptor type I (IL-1R I), IL-1 receptor type II (IL-1R II), IL-1 receptor accessory protein (IL-1RacP), and IL-1 receptor antagonist (IL-1RA). Protein expression was quantified using H-scores and dichotomized by survival-based cut-offs. Circulating IL-1β levels were measured by ELISA in a subset of patients (n = 66). Associations with clinicopathological features, disease-free survival (DFS), and breast cancer-specific survival (BCSS) were evaluated.Results
High intratumoral caspase-1 expression was associated with favorable tumor characteristics, reduced recurrence and metastasis, and improved DFS and BCSS. In contrast, elevated IL-1R II expression correlated with disease recurrence and shorter DFS. IL-1β expression alone showed no independent prognostic significance. Combined analyses demonstrated improved outcomes in tumors with preserved caspase-1 and IL-1β expression. Circulating IL-1β levels were higher in basal-type tumors but showed limited prognostic value.Conclusions
Prognostic effects of IL-1β signaling in early-stage breast cancer depend on inflammasome integrity and receptor regulation rather than cytokine abundance alone. Integrated pathway profiling may improve biologically meaningful prognostic stratification.
Related
- Identification of hepatitis B virus-associated membrane proteins as prognostic biomarkers for hepatocellular carcinoma based on retrospective analysis of integrated membrane proteomics
- Immune and Circulating Biomarkers in Hepatocellular Carcinoma: Prognostic and Predictive Relevance for Immunotherapy
- Circulating calprotectin and S100A8/A9-related biomarkers for diagnosis and prognostic stratification in adult acute infection and sepsis: a systematic review and meta-analysis.
- Targeting autocrine CCL2 signaling reveals oncogenic networks and prognostic biomarkers in medulloblastoma
- Circulating microRNA as biomarkers for predicting cladribine response in multiple sclerosis
BibTeX
@article{hamkarim2026il1β,
title = {{The IL-1β signaling axis as a prognostic determinant in early-stage breast cancer: integrated analysis of tumor and circulating biomarkers.}},
author = {Hersh Abdul Ham-Karim},
journal = {Pathologica},
year = {2026},
month = jun,
doi = {10.32074/1591-951x-1987},
url = {https://europepmc.org/article/MED/43012436},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - The IL-1β signaling axis as a prognostic determinant in early-stage breast cancer: integrated analysis of tumor and circulating biomarkers.
AU - Hersh Abdul Ham-Karim
PY - 2026
DA - 2026/06/01
JO - Pathologica
DO - 10.32074/1591-951x-1987
UR - https://europepmc.org/article/MED/43012436
AB - Background Chronic inflammation contributes to breast cancer progression, yet the prognostic relevance of inflammatory signaling pathways in early-stage disease remains incompletely defined. Interleukin-1β (IL-1β) is a key pro-inflammatory cytokine regulated by inflammasome activation and receptor-mediated signaling. This study evaluated the clinical and prognostic significance of major IL-1β pathway components in early-stage invasive breast cancer.Methods A retrospective cohort of 562 patients with early-stage invasive breast cancer treated between 2018 and 2025 was analyzed. Tissue microarrays were constructed, and immunohistochemistry was used to assess intratumoral expression of caspase-1, IL-1 receptor type I (IL-1R I), IL-1 receptor type II (IL-1R II), IL-1 receptor accessory protein (IL-1RacP), and IL-1 receptor antagonist (IL-1RA). Protein expression was quantified using H-scores and dichotomized by survival-based cut-offs. Circulating IL-1β levels were measured by ELISA in a subset of patients (n = 66). Associations with clinicopathological features, disease-free survival (DFS), and breast cancer-specific survival (BCSS) were evaluated.Results High intratumoral caspase-1 expression was associated with favorable tumor characteristics, reduced recurrence and metastasis, and improved DFS and BCSS. In contrast, elevated IL-1R II expression correlated with disease recurrence and shorter DFS. IL-1β expression alone showed no independent prognostic significance. Combined analyses demonstrated improved outcomes in tumors with preserved caspase-1 and IL-1β expression. Circulating IL-1β levels were higher in basal-type tumors but showed limited prognostic value.Conclusions Prognostic effects of IL-1β signaling in early-stage breast cancer depend on inflammasome integrity and receptor regulation rather than cytokine abundance alone. Integrated pathway profiling may improve biologically meaningful prognostic stratification.
SN - 0031-2983
SN - 1591-951X
ER -